Navigation Links
ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector
Date:8/6/2009

RANCHO CORDOVA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, announced today the introduction of the Res-Q(TM) 60 BMC ("Res-Q") System, an automated cell processing medical device for the concentration of bone marrow-derived stem cells at the point of care.

The Res-Q System processes bone marrow in minutes and delivers a high rate of stem cell recovery. The Res-Q System follows the late 2008 launch of the MXP(TM) MarrowXpress(TM) ("MXP") System, a laboratory device also used to collect stem cells from bone marrow.

The Company plans to initially target the orthopedic regenerative medicine market through its orthopedic distribution partner Celling Technologies ("Celling"), a subsidiary of SpineSmith, LLC. Celling is a leading distributor of orthopedic products based in Texas and also serves as a distributor of the MXP System. In a separate press release today, ThermoGenesis and Celling announced an expanded collaboration between the two firms. Separately, the Company plans to expand Res-Q's applications into the cardiovascular and other non-orthopedic regenerative medicine markets.

"We are excited to add a new member to our stem cell processing product family to help us access the growing regenerative medicine market in a meaningful way. We believe our Res-Q System has considerable advantages over competing products and should help surgeons realize the true value of autologous cellular therapy," said J. Melville Engle, Chief Executive Officer of ThermoGenesis.

"We are delighted to be participating in the launch of the Res-Q System with ThermoGenesis," said Kevin Dunworth, Chief Executive Officer of SpineSmith, LLC. "The device represents a high level of innovative technology and we look forward to building upon our early success with the MXP," he added.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

  • The BioArchive((R)) System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP((R)) AutoXpress(TM) Platform ("AXP"), a proprietary family of automated devices that includes the AXP and the MXP((TM)) MarrowXpress and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MXP is used for isolating stem cells from bone marrow.
  • The Res-Q((TM)) 60 BMC ("Res-Q"), a point of care system that is designed for bone marrow stem cell processing. This product was launched in July 2009.
  • The CryoSeal((R) )FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2009 and 2010, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2010. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

    ThermoGenesis Corp.
    Web site:http://www.thermogenesis.com
    Contact: Investor Relations
    +1-916-858-5107, or
    ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ThermoGenesis Appoints Chief Executive Officer J. Melville (Mel) Engle to Board of Directors
2. ThermoGenesis Corp. to Announce Third Quarter Fiscal 2009 Results on May 6, 2009
3. Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year Milestone
4. ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention
5. ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition
6. ThermoGenesis Corp. Schedules Conference Call/Webcast to Discuss Management Transition
7. ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones
8. ThermoGenesis Reports First Quarter 2009 Results
9. ThermoGenesis Announces 10 New BioArchive(R) System Distributors
10. ThermoGenesis Announces Filing of 510(k) Application for MarrowXpress
11. Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... , ... August 16, 2017 , ... ... Inc. has received a three-year grant totaling $975,000, renewing its funding from the ... and Human Services. , This funding marks, the fourth time the HRSA administration ...
(Date:8/16/2017)... ... August 16, 2017 , ... With a new PD diagnosis every nine ... , The grants are awarded through a competitive application process and reviewed by ... of backgrounds and expertise in all areas relevant to PD research. The SAB ...
(Date:8/16/2017)... VERO BEACH, Fla. (PRWEB) , ... August 16, ... ... living development and management company based in Vero Beach, announced today that two ... Florida Argentum, an organization that represents professionally managed senior living communities in Florida. ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... announces their latest new client win in the healthcare market, with Los Angeles-based ... to support healthcare staff and members. , AHF cares for nearly 800,000 individuals ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... in AED (Automated External Defibrillator) machines to their local business community, Riverfront Fitness ... Arrow Benefits Group. AED machines are an integral part of treating those suffering ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
Breaking Medicine Technology: